13 September 2018
A new report by visiongain predicts that the global vaccine contract manufacturing market will reach $1047.3m in 2019. This forecast and others appear in Vaccine Contract Manufacturing Market Report 2016-2026: Leading Countries, Technologies and Companies, published in December 2015. Visiongain is a business information provider based in London, UK.
Vaccine Contract Manufacturing Market Report 2016-2026: Leading Countries, Technologies and Companies examines the current and future trends in the vaccine contract manufacturing market. Vaccines are a healthcare success, with widespread immunisation eradicating some of the world’s most deadly diseases. The development of new vaccines has historically been limited to a number of large companies due to the high costs involved. However, a growing number of virtual companies and the international demand for new therapeutic vaccines especially, growth in the vaccine contract manufacturing market is accelerating. Another key aspect of the market is the rise of emerging markets as not only a destination for vaccines, but as high quality manufacturing centres for them. While visiongain does not believe this will completely reshape the market, its effects cannot be discounted.
In this report, visiongain examines in detail a number of key national markets (US, Germany, UK, France, Spain, Italy, Japan, China, Russia, Brazil and India), as well as looking at the overall vaccine contract manufacturing market and the key players within it. To give scale to the contract manufacturing business, a global vaccines market forecast is also included. Using visiongain’s experience and market knowledge, as well as a wide variety of sources, forecasts have been built for both national and overall markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.
Visiongain’s report provides revenue forecasts to 2026 for the vaccine contract manufacturing market and its leading national markets. The report discusses selected leading companies which hold significant shares of the market. These companies include Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent, Charles River Laboratories, IDT Biologika, Lonza, Meridian Life Science, Sigma Aldrich Fine Chemicals (Merck) and Synco Bio Partners.
Vaccine Contract Manufacturing Market Report 2016-2026: Leading Countries, Technologies and Companies adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on email@example.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.